Send me a link:

*Text messaging rates may apply.

 Dow Up0.47% Nasdaq Up0.63%

Alger Health Sciences B (AHSBX)

21.44 Up 0.12(0.56%) Jul 9

Profile as of Jun 29, 2014Get Profile for:
Alger Health Sciences B
Alger Funds111 Fifth AvenueNew York, NY 10003
Map
Phone: 800-992-3863
Fund Overview 
Category:Health
Fund Family:Alger
Net Assets:199.89M
Year-to-Date Return:9.07%
Yield:0.00%
Morningstar Rating:2 stars
Fund Inception Date:May 1, 2002
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Dan Chung
Lead Manager since Oct 7, 2005
Daniel C. Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 19 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003 and CEO in 2006. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After law school, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. He joined Simpson Thacher & Bartlett LLP in New York City in 1989 and earned an L.L.M. from New York University. Dan is a CFA charterholder and a member of the CFA Institute. Throughout his tenure at Alger, Dan has made numerous TV appearances, including CNBC’s “The Wall Street Journal with Maria Bartiromo” and Bloomberg’s “Street Fighters.” Dan has also been featured and quoted frequently in Barron’s, Financial Advisor, Forbes, Fortune, Investment News, Smart Money, USA Today and the Wall Street Journal.
Investment Information 
Min Initial Investment:1,000
Min Initial Investment, IRA:500
Min Initial Investment, AIP:500
Min Subsequent Investment:50
Min Subsequent Investment, IRA:50
Min Subsequent Investment, AIP:50
AHSBX can be purchased from 50 brokerages.

Fund Summary 
The investment seeks long-term capital appreciation. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can also invest in derivative instruments.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 17, 2013) : 0.00
Annual Holdings Turnover (Jul 7, 2014) : 115.08%
Average for Category:51.24%
Fees & Expenses 
ExpenseAHSBXCategory Avg
Annual Report Expense Ratio (net):2.12%1.40%
Prospectus Net Expense Ratio:2.12%N/A
Prospectus Gross Expense Ratio:2.12%N/A
Max 12b1 Fee:1.00%N/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: 5.00%2.37%
3 Yr Expense Projection*:964653
5 Yr Expense Projection*:1,3391,025
10 Yr Expense Projection*:2,2562,015
* Per $10,000 invested